Opinion
Video
Author(s):
Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.
New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm
Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL
utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress